Chimerix, Inc. (NASDAQ:CMRX) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET

Company Participants

Michelle LaSpaluto - Vice President-Strategic Planning and Investor Relations

Mike Sherman - President and Chief Executive Officer

Josh Allen - Chief Technology Officer of Imipridones

Mike Andriole - Chief Financial and Business Officer

Allen Melemed - Chief Medical Officer

Conference Call Participants

Kevin Strang - Jefferies

Joseph Thome - TD Cowen

Naureen Quibria - Capital One Securities

Soumit Roy - Jones Research

Operator

Good morning, ladies and gentlemen, and welcome to the Chimerix Fourth Quarter and Year-End 2022 Earnings Conference Call. I would now like to introduce your host for today's call Michelle LaSpaluto, Vice President of Strategic Planning and Investor Relations at Chimerix. Please proceed.

Michelle LaSpaluto

Thank you, Jack. Good morning, everyone and welcome to the Chimerix fourth quarter and year-end 2022 financial and operating results conference call. This morning we issued a press release and our fourth quarter operating update. You can access this press release in the Investors section of the website. With me on today's call are President and Chief Executive Officer, Mike Sherman; Chief Medical Officer, Allen Melemed; Chief Financial and Business Officer, Mike Andriole; and Chief Technology Officer, Josh Allen.

Before we begin, I would like to remind you that the statements made on today's call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and are subject to risks and uncertainties and other factors. These risks and uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. Please refer to our filings with the SEC for a more complete disclosure of these risks and uncertainties.

At this time, I would like to turn the call over to our President and Chief Executive Officer, Mike Sherman.

Mike Sherman

Thanks, Michelle and good morning everyone .Thanks for joining us. We completed an important transition for the company in 2022, monetizing TEMBEXA and fully capitalizing the company without shareholder dilution, establishing runway into 2027 in the process. This was a very attractive transaction for Chimerix with potential for additional meaningful economics in the future.

We’ve now also largely completed our transition responsibilities for TEMBEXA which allows for full focus on our oncology pipeline. Our confidence in these programs continues to grow as we announced new independent survival analysis related to ONC201 or Dordaviprone treatment late last year and now today a clinical milestone for our next generation imipridone ONC206.